Bergeson & Campbell, P.C. articles

EPA recently posted on its Chemical Right-to-Know website a new policy, entitled Policy Regarding Acceptance of New Commitments to the High Production Volume (HPV) Challenge Program, available at www.epa.gov/chemrtk/hpvpolcy.pdf. The policy outlines how companies can commit to sponsor any of the remaining so-called “orphan chemicals,” which include the 300 chemicals that are currently unsponsored under the HPV Chemical Challenge Program. EPA’s website also has a list of the HPV chemic

Much has been written about biotechnology. Indeed, so much has been written that the word `biotechnology` means many things to many people. To the medical/pharmaceutical community, biotechnology is big business, and one that has greatly advanced drug development. To others, crop biotechnology conjures up thoughts of `franken-foods,` and similar provocative images. Biotechnology in environmental remediation and pollution prevention applications represents limitless potential that many believe is

Product Manufacturers often ask whether they should be concerned when a chemical used in the production of one or more of their products becomes the subject of enhanced regulatory review for one reason or another. This question is frequently raised in the context of California Proposition 65 listings; chemicals listed under Proposition 65 become subject to significantly greater scrutiny largely because of hazard warnings that must be communicated under certain circumstances. The answer to their